1 – 3 of 3
- show: 100
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2015
-
Mark
Salvage bortezomib-dexamethasone and high-dose melphalan (HDM) and autologous stem cell support (ASCT) in myeloma patients at first relapse after HDM with ASCT. A phase-2 trial.
(
- Contribution to journal › Article
- 2009
-
Mark
Impaired Stem Cell Mobilization by Fludarabine in MM: Results from a Randomized Phase II Trial
(
- Contribution to journal › Published meeting abstract
- 2006
-
Mark
Autoimmune and chronic inflammatory disorders and risk of non-Hodgkin lymphoma by subtype
(
- Contribution to journal › Article